Standout Papers

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase... 2011 2026 2016 2021 621
  1. Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease (2011)
    Andrew W. Roberts, John F. Seymour et al. Journal of Clinical Oncology

Immediate Impact

7 by Nobel laureates 8 from Science/Nature 66 standout
Sub-graph 1 of 21

Citing Papers

Targeting protein–ligand neosurfaces with a generalizable deep learning tool
2025 StandoutNature
Cell death
2024 Standout
15 intermediate papers

Works of Simon He being referenced

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
2011 Standout

Author Peers

Author Last Decade Papers Cites
Simon He 245 256 91 463 14 833
Giovanna Suppo 322 348 110 317 15 820
Milada S. Vala 171 428 84 347 20 847
W-D Ludwig 146 267 207 393 13 738
Maria Kleppe 296 356 117 448 24 920
C. Vasselon 134 407 111 610 26 936
Betty Glinsmann‐Gibson 142 402 40 413 23 834
MR Grever 388 187 163 296 24 839
Silja Groner 468 412 101 296 14 805
Thet Thet Lin 396 88 44 376 13 726
Nikhil Mukhi 243 130 26 392 14 872

All Works

Loading papers...

Rankless by CCL
2026